Patient Perception Study for AL-4943A
Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Allergic Conjunctivitis
Intervention: AL-4943A (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Alcon Research
Summary
To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis
previously treated with a topical ocular anti-allergy leukotriene-release inhibitor
medication.
Clinical Details
Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Overall Patient satisfaction
Eligibility
Minimum age: 12 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- History of allergic conjunctivitis within last 24 months
- Active signs and symptoms of ocular allergies
Exclusion Criteria:
- Severe or serious ocular condition, ocular surgical intervention, ocular infection
Locations and Contacts
Contact Alcon Call Center for Trial Locations, Fort Worth, Texas 76134, United States
Additional Information
Starting date: September 2010
Last updated: December 14, 2012
|
